Value
-
Biosimilars, Caught my eye, Drug Prices, Drug shortages, ICER, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Obesity, Supply Chain, ValueCaught my eye — 4/11/25
Read more: Caught my eye — 4/11/25Some days I sit down the pottery wheel and I pull 4 bowls or vases in a row that are fantastic. Other days (like, oh, this Sunday and Wednesday) it all collapses. Here is hoping that all of us get better at staying centered and not collapsing. I’d Prefer Not. The 2026 Medicare Advantage and…
-
Caught my eye — 03/28/25
Read more: Caught my eye — 03/28/25There are some weeks you get to Friday and it’s just nice. The anticipation of some dopamine, some relaxation over the weekend. There are other weeks where you barrel into Friday and cram everything in so that 5 pm can arrive with a cocktail. Guess which week I’m having… three quick things you should know.…
-
Caught my eye, Generics, Healthcare Costs, ICER, Inflation Reduction Act, Medicaid, Medicare Negotiation, Medicare Part D, Orphan Drugs, State-based Reform, ValueCaught my eye — 03/07/25
Read more: Caught my eye — 03/07/25Tuesday morning, I spent the first half of the day convinced it was Wednesday, and yet, despite that mental setback, the rest of the week has flown by. Feels like a win. Killing me softly. Overall, glad to see the stories recognizing how the uncertainty of federal research dollars is impacting NIH summer internships, graduate…
-
Caught my eye — 2/21/25
Read more: Caught my eye — 2/21/25Discontinued: A flu vaccination campaign got pulled by the Department of Health and Human Services (HHS). It is off the air and the website was taken offline and now directs users to older information and not the new campaign (“Wild to Mild”.) 1 in 5. Did you know that 1 in 5 people in the…
-
Caught my eye, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Obesity, ValueCaught my eye — 2/14/25
Read more: Caught my eye — 2/14/25Roses are red. Violets are blue. I love health policy, how about you? Public Health Gap: This week a poll found that a quarter of Americans see healthcare access and affordability as their top public health concern and think it would be best solved on the federal level. Among Democrats, 32% had it as their…
-
Caught my eye — 12/6/24
Read more: Caught my eye — 12/6/24When your job is to stay on top of the news but you also just want to turtle a little bit, there are challenges that eventually have to be faced. Skimming the news, here is what caught my eye… 340B Bonanza. I have been devouring the 340B coverage of J&J, Lilly and BMS suing the…
-
Caught my eye — 9/13/24
Read more: Caught my eye — 9/13/24On the pile. 46Brooklyn put out a piece demonstrating the difficulty of understanding drug prices. It is a doozy of a read. A set-aside-time-to-concentrate read. But if you are skeptical about drug pricing and want to lump it all on manufacturers, you should take the time to read it. Big picture, there is no single…
-
340B, Biosimilars, Drug Prices, Generics, Healthcare Costs, Medicare Advantage, Medicare Part D, ValueCaught my eye — 6/21/24
Read more: Caught my eye — 6/21/24You know it is hot when I say, “Let’s go for a walk” and my dog looks at me from the stop of the stairs and refuses to move. At 6:30 in the morning. I hope you’re feeling more motivated than he is. Same same, not different. Late last year, the Medicare prescription drug benefit…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Biosimilars, Caught my eye, Drug Prices, Healthcare Costs, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, ValueCaught my eye — 2/9/24
Read more: Caught my eye — 2/9/24A whirlwind of a week. I regrouped on Wednesday and got a run in and some pottery wheel time and then it all fell apart again (in a good way) on Thursday where I forgot to leave my desk for hours and hours. One of those “I love working” and forget time exists. So much…
Latest news
- Catch as Catch Can
- Make IRA Better
- Spring break broke me
- Caught my eye — 4/11/25
- Caught my eye — 4/4/25
Categories
- 340B (34)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (21)
- Caught my eye (63)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (11)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (32)
- Drug shortages (9)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (10)
- Importation (2)
- Inflation Reduction Act (48)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (16)
- Medicare Negotiation (50)
- Medicare Part D (46)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (8)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (29)
- Reference Pricing (6)
- State-based Reform (15)
- Supply Chain (2)
- Uncategorized (6)
- Utilization Management (1)
- Vaccines (4)
- Value (13)